Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
07 July, 2020 14:13 IST
Aurobindo Pharma receives USFDA approval for Azithromycin Tablets
Source: IRIS | 11 Jul, 2018, 11.57AM
Comments  |  Post Comment

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture Azithromycin tablets 250 mg and 500 mg. Azithromycin tablets are an AB-rated generic equivalent of Pfizer Inc's Zithromax tablets. The product will be launched in July 2018.

Azithromycin tablets are indicated for the treatment of patients with mild to moderate infections. The approved product has an estimated market size of US$ 132 million for the twelve months ending May 2018 according to IQVIA.

This is the 146th ANDA (including 19 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India used for manufacturing oral products. Aurobindo now has a total of 377 ANDA approvals (344 Final approvals including 17 from Aurolife Pharma LLC and 33 tentative approvals) from USFDA. 

Shares of the company declined Rs 8.2, or 1.32%, to trade at Rs 614.95. The total volume of shares traded was 35,975 at the BSE (11.45 a.m., Wednesday).

Aurobindo Pharma Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Security Code type    into this box
Company Update
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer